Ken Griffin United Therapeutics Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$311.04 - $363.55 $715,392 - $836,165	-2,300 Reduced 7.23%	29,500 $10.6 Million
Q2 2024 Aug 14, 2024	SELL	$228.26 - $319.04 $2.03 Million - $2.84 Million	-8,900 Reduced 21.87%	31,800 $10.1 Million
Q1 2024 May 15, 2024	BUY	$210.76 - $249.51 $1.56 Million - $1.85 Million	7,400 Added 22.22%	40,700 $9.35 Million
Q4 2023 Feb 14, 2024	BUY	$214.88 - $256.94 $5.54 Million - $6.63 Million	25,800 Added 344.0%	33,300 $7.32 Million
Q3 2023 Nov 14, 2023	BUY	$211.82 - $248.24 $169,456 - $198,592	800 Added 11.94%	7,500 $1.69 Million
Q2 2023 Aug 14, 2023	SELL	$205.19 - $232.99 $2.2 Million - $2.49 Million	-10,700 Reduced 61.49%	6,700 $1.48 Million
Q1 2023 May 15, 2023	SELL	$212.99 - $276.17 $3.64 Million - $4.72 Million	-17,100 Reduced 49.57%	17,400 $3.9 Million
Q4 2022 Feb 14, 2023	SELL	$205.95 - $280.43 $12.1 Million - $16.5 Million	-58,900 Reduced 63.06%	34,500 $9.59 Million
Q3 2022 Nov 14, 2022	BUY	$203.3 - $244.17 $12.7 Million - $15.2 Million	62,400 Added 201.29%	93,400 $19.6 Million

671

42.3M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.4B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.